Immunic AG is a clinical-stage biotech founded in 2016 and headquartered in Planegg‑Martinsried near Munich, focused on developing oral small-molecule immune modulators. Its two lead programs are IMU-838, a DHODH inhibitor, and IMU-366, an inverse agonist of RORγt, targeting diseases such as ulcerative colitis, Crohn’s disease and psoriasis. IMU-838 was in advanced phase I testing with a planned start of phase II in ulcerative colitis in early 2018, and the company intends to accelerate that phase II development. Immunic is privately held and supported by an international syndicate of life-science investors. The company completed a Series A preferred stock financing totaling €31.7 million, described as one of Europe’s largest biotech Series A rounds. Vincent Ossipow and Jan Van den Bossche were announced as new supervisory board appointees as part of the expanded investor base. Immunic focuses on developing orally available, small‑molecule immune modulators for treatment of immune and autoimmune diseases such as inflammatory bowel disease (IBD) and psoriasis. The company aims to advance its drug development projects to clinical proof‑of‑concept. It plans to use the funds from the recent financing to start developing new therapies for patients suffering from debilitating immune‑system diseases. Immunic was founded in April 2016 by Dr. Manfred Gröppel (Chief Operating Officer) and Dr. Andreas Mühler (Chief Medical Officer). The company is based in Planegg‑Martinsried near Munich, Germany. Financially, Immunic closed a €17.5M Series A to support its early development work.

Total raised

$32M

Funding rounds

2

Latest round

Series A

Latest activity

Sep 2017